Sitemap - 2024 - MS-Selfie
Q&A 32 - Is primary progressive MS different to relapse-onset MS?
Q&A-30 - MS research priorities
Placebo-controlled phase 2 trials
Q&A-29: semaglutide, cannabis and itching
Warning: dangerous counterfeit anti-swallowing devices
Uncertainty associated with MS: are you comfortable with it?
Q&A 28: change in oral cladribine label
Music therapy: under appreciated but not forgotten
Q&A 27: brain reserve, trigonitis and Raynaud's phenomenon
Q&A 26: Anti-CD20 therapy, hypogammaglobulinaemia and infection risk
Q&A 25 - how can MS self-management improve MS outcomes?
How do we make MS services more efficient?
Molluscum contagiosum on fingolimod
Q&A 24 - natalizumab PML, EBV IgM-positive, generic fingolimod
Rectal bleeding: how to approach symptoms that may or may not be related to having MS
Q&A 23 - a clinical trial or not
Will CD19-targeted CAR T-cell therapy cure MS?
Q&A 22 - smouldering MS on ocrelizumab
Will Frexalimab replace the anti-CD20s?
Q&A 21 - diagnosis, relapse and AHSCT
Q&A 20 - remyelination, AHSCT, dental implants, nootropics, ....
Hyper-targeted T-cell therapies
Q&A 19 - Mavenclad, AHSCT & evidence-based medicine
MS-Selfie DMT Infocards version 5.1
Q&A-18: an equivocal new lesion
Is MS a punishment from Allah?
Q&A 17 - beyond no evident inflammatory disease activity or NEIDA